Loading...
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortunately, adults with relapsed or refractory (R/R) B-ALL have...
Na minha lista:
| Udgivet i: | Blood Lymphat Cancer |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7648528/ https://ncbi.nlm.nih.gov/pubmed/33173373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S223894 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|